Daré Bioscience received an additional $1.5 million installment under a multi-year grant, bringing total non-dilutive funding to about $43.3 million for its DARE-LARC1 contraceptive development. The funding supports preclinical work and an Investigational New Drug application. The company is also exploring expanding its programmable drug delivery platform (DARE-IDDS) into treatments for obesity, diabetes, and other chronic diseases. This progress validates the technology and enables further strategic collaborations without diluting shareholders.
Daré Bioscience's recent funding milestone provides context for health sector trends. For readers following health stocks, 71 out of 150 traded on Pluang rose while 72 fell as of Oct 30, 2026 18:43 WIB. Notable movers include BTSG at USD 64.06 with a 6.38% increase and 90% buy orders, TXG at USD 76.56 down 6.12%, and AZN at USD 183.17 up 5.03% with 86% sell orders.
Oxford Square Capital Corp. announced its financial results for Q3 2026, reporting a net asset value (NAV) per share of $1.21, down from $1.29 in Q2. The company declared monthly dividends of $0.015 per share for January, February, and March 2027. Ne...
MADD Canada warns Canadians to avoid impaired driving during Halloween, emphasizing the risks of alcohol, cannabis, and drug-related crashes that cause deaths and injuries annually. The organization urges people to plan safe rides, watch for children...
As Halloween approaches, MADD Canada warns against impaired driving caused by alcohol, cannabis, or drugs, which leads to hundreds of deaths and thousands of injuries annually in Canada. The organization urges people to plan safe transportation if co...
Investec Bank Plc, acting as joint broker for SThree Plc, disclosed share transactions on October 29, 2026. The bank purchased and sold 49,799 ordinary shares of SThree Plc at prices ranging between 297.5 and 306.5 per share. No derivative or option ...
Investec Bank plc, acting as joint broker for Gamma Communications Plc, disclosed its share dealings on October 29, 2026. The bank purchased 218,193 ordinary shares at prices between 1091 and 1094 pence per share and sold 160,410 shares at prices bet...
